Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 70 Show results per page	View Search Criteria \| Help With Results


1.		TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 to 80				Other				2003.333 NCT00133887

Last Modified: 1/14/2009 First Published: 9/23/2006


2.		Phase III Randomized Study of Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus and Methotrexate With or Without Sirolimus in Pediatric Patients With Intermediate-Risk or High-Risk Acute Lymphoblastic Leukemia in Second Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				1 to under 22 at first relapse				NCI				COG-ASCT0431 ASCT0431, COG-PBMTC-ONCO51, NCT00382109


3.		Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				12 to 65				Other				PROGAST NCT00180089


4.		Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Active				18 to 75				Other				ZSH-LCI-FJ-0002 NCT00554125


5.		Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Active				2 to 55				NCI, NHLBI				385 BMT CTN 0402, U01 HL069294-05, NCT00406393


6.		Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				06-065 X05175, NCT00369226


7.		Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				70 and under				Other				2005-0508 NCT00402558

Last Modified: 7/11/2007 First Published: 1/5/2007


8.		Phase I/II Study of Cytoreduction Therapy Comprising Clofarabine, Melphalan, and Thiotepa Followed By Allogeneic Unmodified Hematopoietic Stem Cell Transplantion in Patients With High-Risk and/or Advanced Hematologic Malignancies or Other Diseases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				Under 55				NCI				MSKCC-06125 NCT00423514


9.		Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 to 65				Other				2006-0803 NCT00410982

Last Modified: 5/15/2007 First Published: 3/2/2007


10.		Phase I/II Study of Cyclophosphamide and Busulfan Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Idiopathic Myelofibrosis

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				65 and under				NCI				FHCRC-2130.00 6447, NCT00445744

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute